NASDAQ:SNOA - Sonoma Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.43 -0.07 (-4.67 %)
(As of 10/22/2018 04:00 PM ET)
Previous Close$1.50
Today's Range$1.41 - $1.55
52-Week Range$1.31 - $5.92
Volume37,084 shs
Average Volume97,171 shs
Market Capitalization$9.72 million
P/E Ratio-0.45
Dividend YieldN/A
Beta1
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions. It also provides Mondoxyne, a doxycycline-based prescription oral tetracycline antibiotic used as a treatment for acne vulgaris; Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; and Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNOA
CUSIPN/A
Phone707-283-0550

Debt

Debt-to-Equity Ratio0.01
Current Ratio4.02
Quick Ratio3.27

Price-To-Earnings

Trailing P/E Ratio-0.45
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.66 million
Price / Sales0.56
Cash FlowN/A
Price / CashN/A
Book Value$2.48 per share
Price / Book0.58

Profitability

EPS (Most Recent Fiscal Year)($3.16)
Net Income$-14,320,000.00
Net Margins-83.05%
Return on Equity-97.88%
Return on Assets-76.84%

Miscellaneous

Employees79
Outstanding Shares6,480,000
Market Cap$9.72 million

Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) issued its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.09. The business had revenue of $4.37 million for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 97.88% and a negative net margin of 83.05%. View Sonoma Pharmaceuticals' Earnings History.

When is Sonoma Pharmaceuticals' next earnings date?

Sonoma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for Sonoma Pharmaceuticals.

What price target have analysts set for SNOA?

2 brokerages have issued twelve-month price objectives for Sonoma Pharmaceuticals' stock. Their predictions range from $3.00 to $7.00. On average, they expect Sonoma Pharmaceuticals' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 249.7% from the stock's current price. View Analyst Price Targets for Sonoma Pharmaceuticals.

What is the consensus analysts' recommendation for Sonoma Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sonoma Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sonoma Pharmaceuticals.

What are Wall Street analysts saying about Sonoma Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sonoma Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. " (8/29/2018)
  • 2. Maxim Group analysts commented, "Sonoma reported strong sequential growth (F3Q18) with gross revenues of $4.8M driven by US and Latin America, up 46% versus the same period a year ago. US Dermatology was $2.2M up 78% versus last year. New products were a key driver of growth for the company. Net revenues were $2.9M, also showing strong growth at the prescribers level. The impact of 30 sales reps and five senior managers is manifesting as top line revenues. US revenues now represent more than 2/3 of all revenues with solid margins. The company closed the quarter with $8.6M in cash on the balance sheet." (2/8/2018)

Who are some of Sonoma Pharmaceuticals' key competitors?

Who are Sonoma Pharmaceuticals' key executives?

Sonoma Pharmaceuticals' management team includes the folowing people:
  • Mr. James Schutz, CEO, Pres & Director (Age 55)
  • Mr. Robert E. Miller, CFO & Corp. Sec. (Age 76)
  • Mr. Marc Umscheid, Chief Operating Officer (Age 49)
  • Dr. Robert Northey, Exec. VP of R&D (Age 61)
  • Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 54)

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $1.43.

How big of a company is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals has a market capitalization of $9.72 million and generates $16.66 million in revenue each year. The company earns $-14,320,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. Sonoma Pharmaceuticals employs 79 workers across the globe.

What is Sonoma Pharmaceuticals' official website?

The official website for Sonoma Pharmaceuticals is http://www.sonomapharma.com.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 1129 NORTH MCDOWELL BLVD., PETALUMA CA, 94954. The company can be reached via phone at 707-283-0550 or via email at [email protected]


MarketBeat Community Rating for Sonoma Pharmaceuticals (NASDAQ SNOA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  321
MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNOA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel